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Abstract
Background: High-degree microsatellite instability (MSI-H) is a feature of approximately 15% of
sporadic colorectal cancers. Patients with MSI-H cancers have been reported to have a better
prognosis than those with non-MSI-H cancers. The MSI-H subset is also characterised by a dense
infiltrate of intra-epithelial lymphocytes and the hypothesis that the latter represents an efficacious
immune response contributing to improved outcome is very attractive.
Methods: Data for this review were identified by searches of MEDLINE, PubMed, and cross
references from relevant articles using the search terms 'microsatellite instability', 'colorectal
cancer' and 'immunology', 'immune response' or 'immunogenicity'.
Results: A total of 38 articles were identified by the search criteria and a further 95 articles by
cross-referencing. The relevance of the articles to be interviewed was established by hand
searching. Out of a total of 133 articles identified, 47 articles were rejected due to lack of relevance.
A total of 86 articles were included in the review, pertaining to microsatellite instability in
colorectal cancer, and immune mechanisms in colorectal cancer.
Conclusion: It is suggested that this distinct group of colorectal cancers may have inherent
immunogenic properties and that further elucidation of these may be invaluable to the development
of successful immunotherapy.
Background
Colorectal cancer remains a leading cause of cancer-
related mortality and morbidity in the Western world. In
the UK it is the third commonest cancer, after lung and
breast, with more than 35,000 new cases diagnosed each
year and the second commonest cause of cancer-related
mortality with approximately 16,000 deaths per year
(CancerStats: Large Bowel – UK, Cancer Research UK
2003, http://www.cancerresearchuk.org[1]). Complete
surgical resection is the cornerstone of curative treatment.
Other treatment modalities, such as chemotherapy and
radiotherapy, administered before or after surgery, are
used to counteract disease progression particularly in
Stage III and IV disease [2,3]. Despite continuing technical
advances in the use of these techniques the improvement
in overall five-year survival rate has been limited (5–6%).
This fact, along with the high proportion of patients who
present with tumours not amenable to surgery, drives the
search for additional modalities of anti-cancer treatment.
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Immunotherapy, the use of the adoptive immune system
to target cancer cells, holds much promise in this regard.
The concept of immune surveillance, whereby the host
immune system detects and removes cancerous cells,
arose from the observation that immunodeficiency pre-
disposes to the development of malignancies. Further-
more, it has been proposed that rare reports of solid
tumour regression are the result of an anti-tumour
immune response. Early work suggested that such anti-
tumour responses were impotent against colorectal cancer
[4-6]. However, evidence that colorectal malignancies
may generate tumour specific antigens (TSA's) has encour-
aged considerable efforts to develop means of harnessing
the host immune system to combat colorectal cancer. The
use of immunotherapeutic approaches in colorectal can-
cer has evolved substantially (not reviewed here) and now
focuses on the use of tumour specific antigens. This
involves either passive immune therapy with antibodies
targeted directly to tumour cells or by active immune ther-
apy via vaccination with tumour cells, tumour cell lysates,
peptides, carbohydrates, gene constructs encoding pro-
teins, or anti-idiotypic antibodies that mimic TSA's.
Despite some successes these techniques are still in their
infancy and many hurdles remain, largely because our
understanding of the biology of host-tumour interactions
in colorectal cancer remains elementary.
In the last ten years a distinct subset of colorectal cancer,
with characteristics of widespread microsatellite instabil-
ity, has emerged as a group in which immune responses
may be pronounced. Clearly, if this type of colorectal can-
cer does indeed have particular immunogenic features, its
study should provide vital advances in our understanding
of colorectal tumour immunology. Here we review the lit-
erature in relation to putative immune responses in color-
ectal cancers with microsatellite instability.
Microsatellite instability (MSI)
It is now clear that colorectal cancers may arise by a
number of distinct molecular pathways. The "classical
pathway" characterised by chromosomal instability (CSI)
and a series of genetic events that drives the progression
from normal colon through adenomatous polyp to inva-
sive cancer accounts for 50–60% of cancers [7]. However,
this is but one of many alternate pathways and one of
these, involving mismatch repair dysfunction, leads to
colorectal cancer characterised by microsatellite instabil-
ity. High-degree microsatellite instability (MSI-H) is a fea-
ture of most colorectal cancers arising as part of the
hereditary non-polyposis colorectal cancer (HNPCC) syn-
drome and also 15–20% of sporadic colorectal cancers
[8].
Microsatellites are short segments of repetitive DNA bases
found throughout the genome but mainly located in
intronic (non-coding) segments. Due to their repetitive
nature they are prone to insertion and deletion mutations
during DNA replication, which commonly introduces
such errors at a rate of 1 in 100,000 base pairs copied. The
majority (99%) of these errors are detected and corrected
by the inherent proof reading capabilities of DNA
polymerase enzymes. A small proportion of mismatches
that are missed by this mechanism are normally identified
and corrected by a group of proteins collectively termed
the mismatch repair (MMR) system [9]. Dysfunction of
the MMR system allows the accumulation of replication
errors and leads to microsatellite instability [10], defined
as "a change of any length due to either insertion or dele-
tion mutations of repeating units in a microsatellite" [11].
Mismatch repair dysfunction
The molecular mechanisms that underlie MMR dysfunc-
tion are different in familial and sporadic colorectal can-
cers. In HNPCC colorectal cancers a germline mutation
within an individual mismatch repair gene is inherited
and a subsequent "second hit" [Knudson's 'two-hit'
hypothesis [12]] in the normal allele leads to mismatch
repair deficiency. The commonly affected genes are
hMLH1, hMSH2 and to a lesser extent PMS2, and their
involvement predicts the development of extensive micro-
satellite instability [13]. By contrast, cancer cells with iso-
lated mutations in hMSH3 and hMSH6 continue to
maintain some mismatch repair function [14-16].
In sporadic MSI colorectal cancers genetic alterations in
MMR genes are relatively rare. Instead epigenetic modula-
tion of MMR genes, particularly hMLH1, such as hyper-
methylation of the promoter region leads to silencing and
MMR deficiency [17,18]. Hypermethylation is characteris-
tic of a subset of colorectal cancers designated the CpG
island methylator phenotype (CIMP+) that is relatively
common in right sided tumours [19]. Sporadic MSI-H
colorectal cancer appears to represent a subset of the
methylator phenotype in which global hypermethylation
silences MMR genes. These cancers have biological prop-
erties quite distinct from that of HNPCC tumours, in
which MMR dysfunction is the sole abnormality, whereas
widespread changes in methylation targets the expression
of numerous other genes not involved in the MMR path-
way [20].
All colorectal cancers display some degree of microsatel-
lite instability if enough markers are studied [21]. In 1997
an International Collaborative Group laid down guide-
lines for the identification and assessment of microsatel-
lite instability [22]. They classified tumours into
microsatellite stable (MSS) and two groups of microsatel-
lite unstable cancers, discriminated by their degree ofWorld Journal of Surgical Oncology 2005, 3:26 http://www.wjso.com/content/3/1/26
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instability: high (MSI-H) or low (MSI-L). Two mononu-
cleotide microsatellite markers (BAT-25 and BAT-26) and
three dinucleotide markers (D2S123, D5S346 and
D17S250) were chosen as a panel to be studied for assig-
nation of MSI status. Tumours displaying instability in
two or more markers were designated MSI-H, instability
in only one marker was designated MSI-L and if no mark-
ers were affected the tumour was designated MSS. There is
now a growing consensus that the MSI-H clinico-patho-
logical phenotype is characterised particularly by instabil-
ity in the mononucleotide markers [21]. Colorectal
cancers with MSI-H clearly demonstrate distinct biologi-
cal behaviour whereas MSI-L cancers are less well charac-
terised and are often grouped with cancers that show no
instability (MSS) [23]. The focus of this review is the clin-
ico-pathological phenotype characteristic of sporadic
MSI-H colorectal cancer.
MSI-H colorectal cancer
Sporadic MSI cancers do not harbour some of the charac-
teristic features or gene mutations associated with CSI
cancers, such as aneuploidy and p53 mutation. A number
of human genes implicated in pathways regulating growth
control and apoptosis, for example IGF-IIR, TGFβ -RII and
BAX, contain microsatellite repeats within the coding
regions of their transcribed sequences. More recently the
BRAF gene has been noted to be commonly mutated in
sporadic MSI-H, as well as in serrated polyps, suggesting
that serrated polyps are likely precursors of these cancers
[20]. It has been suggested that instability of such
sequences plays a role in the progression of disease, pre-
sumably by altering gene activity [8,24]. Altered regula-
tion of all or some of these genes may be involved in
cancer development but precise mechanisms are yet to be
identified.
Colorectal cancers with MSI-H also have distinct clinico-
pathological characteristics. Sporadic MSI-H tumours are
associated with the right side of the colon and display
marked lymphocyte infiltration into tumour epithelium,
stroma, peri-tumoral cuffs and Crohn's type reactions
[25]. Sporadic MSI-H colorectal cancers have also specifi-
cally been associated with medullary-type poor differenti-
ation, high mucin content and reduced lymph node
involvement [20,25].
MSI-H and improved survival
Early reports on microsatellite instability noted an associ-
ation of MSI with improved patient survival [26,27].
Some small studies have failed to reproduce this finding
[28-30] but generally the association of MSI-H with
improved survival in sporadic cancers has been confirmed
in larger studies [31-33]. Many further studies have fol-
lowed that confirm improved prognosis for patients with
sporadic MSI-H colorectal cancer, particularly in lymph
node positive cancers, and the link to improved survival
has now been confirmed in a systematic review [34].
One explanation offered for the improved survival of MSI-
H colorectal cancer patients has been that these cancers
may be more sensitive to adjuvant chemotherapy. Indeed
early retrospective analyses suggested that cancers with
high-degree microsatellite instability had improved
response to 5-Fluorouracil (5FU)-based adjuvant chemo-
therapy [35-37]. However, these data were retrospectively
derived from non-randomised groups and the effects of
small numbers, younger age of patients receiving chemo-
therapy, and different responses of right and left-sided
tumours might have confounded the findings. In contrast,
two studies have reporting retrospective data derived from
randomised control trials of chemotherapy conclude that
5-FU regimes confer no benefit in sporadic MSI-H color-
ectal cancers and may even be detrimental [38,39]. There
is clearly a need for robust prospective randomised con-
trolled trials to evaluate the effects of 5-FU, and other
agents, on survival with respect to MSI status.
An alternative explanation for the improvement in patient
survival is one of enhanced host immune response. An
immunohistochemical study noted that the improved
survival of patients with MSI-H was associated with the
higher frequency of activated tumour infiltrating lym-
phocytes in these cancers [40]. Consequently, it has been
suggested that these lymphocytes may actually represent a
host immune response that contributes to improved sur-
vival and subsequent work has confirmed a possible link
[41]. The hypothesis that colorectal cancers with MSI-H
are more immunogenic than microsatellite stable cancers
is very attractive, as study of these cancers may provide
crucial insights into colorectal cancer immunology. The
further elucidation of immune responses to colorectal
cancer in vivo is crucial to the continuing development of
immunotherapy.
MSI-H and tumour immunogenicity
Current concepts in solid tumour immunology identify
certain features that are fundamental to the stimulation of
an anti-tumour response [Reviewed in [42]]. Successful
immune response requires a cancer to possess antigens
that can be recognised as non-self during immune surveil-
lance. In MSI-H colorectal cancer the accumulation of
errors in microsatellites, that reside in gene exons, leads to
the generation of a large number of abnormal peptides
due to frameshift mutations: the so-called "mutator phe-
notype" [43]. Clearly, such an array of abnormal peptides
might represent a pool of TSA's that render MSI-H
tumours inherently more detectable by the host immune
system.World Journal of Surgical Oncology 2005, 3:26 http://www.wjso.com/content/3/1/26
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Studies on abnormal peptides characteristic of MSI-H
have demonstrated their potential for immune recogni-
tion. A peptide generated by frameshift mutations in
TGFβ RII, characteristic of the mutator phenotype, has
been used to pulse dendritic cells, which in turn induced
activated cytotoxic (CD8+) T cells [44]. One cytotoxic T
cell clone demonstrated specific anti-tumour activity
against a cell line expressing this peptide in in vitro condi-
tions. The same group have also identified MHC class-II
restricted epitopes by induction of helper (CD4+) T cells
from the peripheral blood mononuclear cells of normal
volunteers and MSI-H colorectal cancer patients [45].
They also demonstrated that tumour infiltrating lym-
phocytes derived from an HNPCC MSI-H cancer recog-
nised this frameshift-mutation-derived peptide but
unusually the infiltrate in this tumour was predominantly
CD4+ T cells. More recently, another group have identi-
fied several other frameshift-mutation-derived peptides as
potential tumour specific antigens (TSA's) by using SEREX
(serological analysis of recombinant cDNA expression
cloning) [46]. They also detected IgG antibodies specific
to these peptides only in the MSI-H cancer patients. In an
HNPCC patient they demonstrated an antibody specific
to a mutated CDX2 peptide that was found in the tumour
tissue of the patient and this antibody was not seen in any
of the other patients. Interestingly, the antibody disap-
peared seven years after curative resection. These observa-
tions lend significant support to the notion that MSI-H
TSA's are effectively recognised by the host immune
response and an immune response is induced, but more
work is needed to confirm that findings in HNPCC
patients are mirrored in sporadic MSI-H cancers.
Tumour specific antigens must be appropriately presented
to the host immune system if a specific immune response
is to occur. This normally requires the presentation of
antigen in conjunction with the appropriate Major Histo-
compatibility Complex (MHC) molecules that interact
with the T cell receptor (TCR): Class I MHC for presenta-
tion to cytotoxic (CD8+) T cells and Class II MHC for pres-
entation to helper (CD4+) T cells [47]. It has been argued
that MSI-H colorectal cancers are incapable of eliciting
cytotoxic responses in vivo due to the truncation of β 2-
microglobulin that is characteristic of these tumours [48].
The β 2-microglobulin protein is an essential co-factor for
MHC Class I and its defective function would render effec-
tive presentation of antigens impossible. However, whilst
this defect negates antigen presentation by the tumour
itself there is now considerable evidence that the direct
presentation of antigen by a tumour may be relatively
unimportant. Instead, the concept of "cross-priming" in
which APC's such as dendritic cells, and to a lesser extent
macrophages, pick up antigens released by dead tumour
cells and subsequently present them to T cells may be
more important in vivo [49,50]. Thus, β 2-microglobulin
mutations may be of relatively little importance. Instead a
pool of abnormal peptides generated by the mutator phe-
notype may be recognised and harvested as TSA's by
immature dendritic cells. On acquisition of non-self anti-
gens these dendritic cells mature into professional APC's,
with a natural propensity to appropriately present antigen
and co-stimulate T lymphocytes [50].
Antigen presenting cells may obviate the need for direct
presentation by tumour cells and cross-priming may
involve the use of HLA Class II machinery. Immunohisto-
chemical studies have demonstrated that HLA Class II
expression is increased in MSI-H colorectal cancer com-
pared to MSS cancers, although this was not associated
with improved survival [51]. Additionally, molecular
analyses using single subtraction hybridisation [52] and
oligonucleotide microarrays [53] have also confirmed
increased Class II mRNA levels in MSI-H colorectal cancer.
These findings support the in vitro studies of tumour infil-
trating lymphocytes in MSI-H colorectal cancer, men-
tioned earlier, that demonstrated HLA Class II restricted T
helper cell activity and the presence of dendritic cells
[44,45]. Either of these two populations may provide an
alternative pathway by which cytotoxic T cells may be
recruited and stimulated indirectly, but more work is
needed to ascertain whether cytotoxic populations them-
selves are capable of recognising TSA's.
It has recently become evident that appropriate co-stimu-
lation is pivotal to effective antigen presentation [54]. Co-
stimulation refers to the interaction between surface mol-
ecules on the antigen-presenting cell (APC), such as CD80
(B7.1) and CD86 (B7.2), and surface molecules on the T
cells (CTLA-4, OX40, CD40-L). If these molecules do not
bind each other during antigen-presentation then co-
stimulation fails and the T cells become anergic, i.e. inef-
fective and tolerogenic [54]. A microarray analysis com-
paring the gene expression profiles of MSI-H colorectal
cancers to MSS counterparts demonstrated increased sig-
nal intensity of CD80 and CD86 in the former group [53]
but further studies to validate these findings are still
required. After appropriate antigen-presentation and co-
stimulation lymphocytes are activated in a tumour-spe-
cific response [49,54]. They may then migrate to the
tumour, infiltrate it and release mediators that can induce
tumour cell death [47].
MSI-H colorectal cancer and lymphocyte infiltration
For many years the presence of a pronounced infiltrate of
lymphocytes in colorectal cancer has been associated with
improved prognosis [55,56] but conclusions have been
confounded by inconsistencies. Lymphocytes associated
with colorectal cancer can be sub-divided into those that
invade tumour epithelium (intra-epithelial lymphocytes,
IEL's), those confined to the stroma or those aggregatedWorld Journal of Surgical Oncology 2005, 3:26 http://www.wjso.com/content/3/1/26
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around the tumour (peri-tumoral lymphocytes). Previous
studies on the significance of tumour infiltrating lym-
phocytes have been confusing due to variability in the def-
inition of the subset being studied. More recently it has
been shown that the presence of IEL's is positively associ-
ated with an improved survival in colorectal cancer in gen-
eral [57] and specifically MSI-H colorectal cancer [41]. It
has been suggested that they IEL's may represent evidence
of an immune response to tumour antigens.
In a study specific to MSI-H colorectal cancer, Dolcetti and
colleagues demonstrated increased immunostaining for
IEL's when compared to MSS cancers [58]. These lym-
phocytes were shown to be predominantly CD8+ in keep-
ing with a cytotoxic lymphocytic response and these
findings have been confirmed by other groups using
immunohistochemistry and RT-PCR [41,59]. However,
debate continues as to whether these lymphocytes are of
the αβ T cell receptor lineage that are involved in tumour
infiltration from the circulation or whether they are
derived from γδ  T cells that normally reside in the gas-
trointestinal tract [60]. The αβ T cell phenotype represents
lymphocytes that are targeting the tumour after antigen
priming in lymphoid tissue, whereas the γδ  T cells might
represent a proliferation of lymphocytes resident in
tumour epithelium. These characteristics of the lym-
phocyte infiltrates need further clarification.
One immunohistochemical study, involving relatively
small numbers and two groups that differed considerably
in size (n = 17 v n = 7), has noted the increased presence
of CD8+ CD103+ (α Eβ 7+) lymphocytes in MSI-H colorec-
tal cancer compared to MSS cancers [61]. The presence of
CD103+ cells was much higher in tumour tissue than in
adjacent colon in both groups and the authors' postulate
that this integrin subunit, which binds to E-Cadherin, has
a role in migration of lymphocytes from stroma to tumour
epithelium. They suggest that the differences in lym-
phocyte infiltration between the two groups are likely to
be due to increased expression of CD103 by local lym-
phocytes in MSI-H cancer that promotes infiltration into
the tumour. They also postulate that local mediators
released by the tumour, such as TGFβ -I rather than a sys-
temic immune response, leads to CD103 upregulation,
but they provide no evidence to support this. The expres-
sion of CD103 may well facilitate lymphocyte infiltration
from stroma to tumour, but whether the difference in IEL
numbers between MSI-H and MSS is due to tumour-
derived mediators or an immune response is unclear from
this study [61].
The increased expression of cytolytic mediators by IEL's in
MSI-H colorectal cancer suggests that these cytolytic T-
cells are indeed activated. Increased expression of per-
forin, granzyme B and granulysin in MSI-H colorectal can-
cers [53,59,62] suggests that IEL infiltrates are attempting
to induce tumour cell death. This is lent further credence
by the finding that the activation marker IL2Rα  is also
expressed more significantly in these tumours [59]. No
single activation marker has been shown to correlate with
survival in studies to date but this may well due to the
complexities of immune responses.
The process of lymphocyte infiltration and anti-tumour
activity is also influenced by the differential activity of
helper (CD4+) T lymphocyte subsets and local cytokine
profiles. Immune responses are promoted by the Th1 sub-
set of CD4+ lymphocytes and their associated cytokines
[Interferon (IFN)-γ , Tumour necrosis factor (TNF)-α ,
Interleukin (IL)-2 and IL-12). By contrast the Th2 subset
of CD4+ lymphocytes and cytokines such as IL-10 pro-
mote tolerance to unrecognised antigens and prevent suc-
cessful antigen-specific responses. A microarray analysis
performed in our laboratory has demonstrated the upreg-
ulation of several pro-inflammatory cytokines in MSI-H
colorectal cancer [53]. As well as the common players this
analysis has identified potentially crucial roles for IL-18
and IL-15, both of which are capable of co-ordinating
innate and acquired responses [63,64]. Clearly, activity of
these interleukins should promote the likelihood of a suc-
cessful immune response.
This microarray analysis also demonstrated that the heat
shock protein family is up-regulated in MSI-H colorectal
cancer [53]. This is highly significant in the context of pre-
vious work by Srivastava and others that has demon-
strated the role of heat shock proteins in innate and
antigen-specific immune responses [65,66]. Heat shock
proteins act as chaperones that are actively involved in
regulating the folding of newly synthesised proteins [67].
Indeed their name derives from the observation that these
proteins are over-expressed in response to heat shock, and
other stresses, that lead to native protein unfolding. The
native fold of a protein is encoded by its amino acid
sequence and it is therefore attractive to suggest that can-
cers with high-degree microsatellite instability, that gener-
ate large numbers of abnormal proteins with consequent
misfolding, might excite a heat shock protein response.
Heat shock proteins are used as natural adjuvants in
immunotherapy trials and their up-regulation in MSI-H
tumours may reflect a similar function in naturally occur-
ring immune responses [68,69].
Our microarray findings have been validated using quan-
titative real-time RT-PCR across several genes of interest
and demonstrate clear differences in the tumour biology
of MSI-H and MSS cancers at the mRNA level.World Journal of Surgical Oncology 2005, 3:26 http://www.wjso.com/content/3/1/26
Page 6 of 9
(page number not for citation purposes)
Tumour escape and counter-attack
To counteract immune surveillance solid cancers may
employ mechanisms to evade the immune system. Several
possible methods of immune escape have been identified
in colorectal cancer, such as the down-regulation of MHC
proteins and co-stimulatory molecules [70,71]. The avail-
able evidence suggests that MSI-H colorectal cancers dem-
onstrate higher levels of MHC Class II machinery than
MSS counterparts, although the inefficacy of HLA Class I
molecules in MSI-H tumours has been proposed as a
means of tumour escape [48]. The significance of this in
light of the potential for immune cross-priming is contro-
versial, as discussed earlier.
Alternative mechanisms of immune escape identified in
colorectal cancer include the release of mediators that
suppress the function of tumour infiltrating lymphocytes:
so-called "tumour counter-attack". In the past in vitro
studies of lymphocytes infiltrating colorectal cancer have
failed to demonstrate specific anti-tumour activity even
though analysis of their receptor usage strongly suggested
antigen-specificity [72,73]. These studies did not discrim-
inate tumours according to microsatellite status but one
explanation offered for the findings was that the presence
of anti-lymphocyte agents, released by the tumour itself,
neutralized the activity of tumour infiltrating lym-
phocytes. The fatty acid synthase (Fas)/Fas-Ligand system
has been implicated as a pathway of colorectal cancer
counter-attack [74]. Fas-L released by colorectal cancers
may bind to Fas receptors on infiltrating lymphocytes and
induce their apoptosis. Infiltrating lymphocytes may
release Fas-L themselves but colorectal cancers evade the
detrimental effects of this by uncoupling their Fas recep-
tors from the intra-cellular machinery that mediates cell
death. An immunohistochemical study examining mem-
brane-bound Fas-L expression found that, contrary to
expectation, Fas-L expression is not increased in MSS can-
cers and thus does not explain the less prominent lym-
phocyte infiltrates seen in these cancers [75]. The authors
conclude that some other, as yet unidentified, mechanism
of counter-attack must exist in these cancers to account for
the reduced infiltrate in MSS colorectal cancer rather than
attributing the difference to variable degrees of immuno-
genicity.
MSI-H colorectal cancer and apoptosis
Dolcetti and colleagues showed that MSI-H colorectal
cancers stained significantly more heavily for markers of
apoptotic cell death [76]. Subsequent follow-up analysis
of the patients from whom the tumours had been
removed showed that increased apoptosis counts corre-
lated well with improved survival [40]. However, Michael-
Robinson and co-workers also studied apoptosis in these
cancers using TUNEL and though they confirmed the pres-
ence of more apoptotic cells, they found no co-localisa-
tion between these cells and infiltrating lymphocytes [77].
They concluded therefore that increased T cell infiltrates
were not likely to be responsible for more marked tumour
cell death. However, it may be argued that the release
cytokine mediators of target cell death by infiltrating lym-
phocytes may render the need for direct co-localisation
obsolete. In our opinion as MSI-H colorectal cancer does
appear to be infiltrated by an activated cytotoxic T cell
population and the tumours show high levels of apopto-
sis the two are likely to be linked but we acknowledge the
need for further clarification.
An alternative explanation for the increased apoptosis
observed in MSI-H colorectal cancer has been the theory
of "effete malignancy". This concept proposes that the
mutator phenotype affects peptides or pathways involved
in cell processes fundamental to life. Thus, the accumula-
tion of mutations adversely influences the tumour cells'
viability and hence, leads to apoptotic cell death [78]. The
anti-apoptotic bcl-2 protein has been noted to be under-
expressed in MSI-H colorectal cancers [79] but the pro-
apoptotic gene BAX also appears to be a common target
for mutation in the MSI pathway [80], an event that may
promote clonal expansion and tumourigenesis. These
observations confirm the complex role of apoptosis in
tumour development and progression.
The apoptosis observed in these cancers, whether induced
by effete malignancy or an immune response, is of signif-
icance for another reason. The death of tumour cells
releases intra-cellular proteins into the tumour micro-
environment. This would be a vital step in the promotion
of TSA release, recognition and presentation to the host T
lymphocytes. It might also release heat shock proteins,
upregulated in MSI-H colorectal canecr, which may pro-
mote both innate and antigen-specific arms of the
immune response. The importance of dendritic cells in
immune responses has already been mentioned [49] and
immunohistochemical analysis of colorectal cancer has
demonstrated the presence of dendritic cells at tumour
margins [81]. The presence of this population has not
been evaluated in MSI-H cancers specifically but the pres-
ence of dendritic cell infiltrates has been associated with
reduced tumour progression in colorectal cancer [82].
Conclusion
Clearly, the mutator phenotype may influence the func-
tion of several cellular processes and these may include
those that are designed to nullify the host response.
Equally it has been suggested that it is the effect of micro-
satellite instability on other cellular processes, unrelated
to tumour immunology, which leads to the survival ben-
efit observed in MSI-H colorectal cancer. Effete malig-
nancy may, for instance, limit a tumour's ability grow and
survive [78]. Alternatively processes critical to tumourWorld Journal of Surgical Oncology 2005, 3:26 http://www.wjso.com/content/3/1/26
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metastasis may be adversely affected by the mutator phe-
notype. The down-regulation of VEGF in MSI-H colorectal
cancer is a one example of how these tumours may suffer
reduced metastatic potential [83]. Certainly many of the
biological characteristics of MSI-H, such as diploidy, wild-
type p53 expression, activating β -catenin mutations and
the CIMP+ phenotype, have all been associated with
improved prognosis [84]. However, the effects of all these
factors and that of an immune response may be additive,
rather than exclusive and they may all contribute to the
improvement in outcome.
There is now an accumulation of evidence that promotes
the argument that MSI-H colorectal cancer is subject to a
marked, possibly antigen-specific, immune response. We
acknowledge that this may not be the sole determinant of
improved prognosis although it seems likely to be a major
influence. We believe that MSI-H may be a natural para-
digm of host-tumour interactions in immunogenic color-
ectal cancers and as such further studies are required to
clarify the nature of immune responses in these tumours.
The use of heat shock proteins and abnormal peptides,
derived from frameshift mutations in coding microsatel-
lites, already hold promise in advancing the field of
immunotherapy [85,86]. Ultimately the demonstration
of specific anti-tumour activity in cytotoxic lymphocytes
from patients with MSI-H colorectal would provide the
best evidence in support of such a response. Such studies
should enhance our understanding of the immune
responses in MSI-H tumours and the tumour immunol-
ogy of colorectal cancer in general. This may be crucial to
the advance of efforts in the field of immunotherapy.
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